KVUE This administration is a complete joke, you don’t even need to dig for a stock anymore. They do something crazy, and the opportunity lands right in front of you. I went in heavy on this one, entered at $16.24, and my target is $22.Kenvue, Inc. stock forum
KVUE This administration is a complete joke, you don’t even need to dig for a stock anymore. They do something crazy, and the opportunity lands right in front of you. I went in heavy on this one, entered at $16.24, and my target is $22.
KVUE (previously J&J’s consumer unit) has defended hundreds of lawsuits alleging prenatal acetaminophen (Tylenol) exposure is linked to autism/ADHD—most notably in a federal multidistrict litigation in SDNY that Judge Denise Cote dismissed after excluding plaintiffs’ experts, with appeals now pending. Kenvue continues to contest such claims and maintains Tylenol’s safety. For context, major medical bodies (ACOG, AAP) say a causal link hasn’t been established, while the FDA recently signaled label changes noting a possible association during pregnancy—positions that are currently being debated and have helped reignite litigation headlines.
Kenvue separation news (Johnson & Johnson)
investors.kenvue.com/financial-news/news-details/2023/Kenvue-Becomes-a-Fully-Independent-Company-Following-Final-Separation-from-Johnson--Johnson/default.aspx
Coverage of Tylenol autism litigation dismissal (Reuters)
reuters.com/legal/tylenol-autism-adhd-lawsuits-dismissed-us-judge-2023-12-18
FDA communication on acetaminophen and neurodevelopment (FDA label update discussion)
fda.gov/drugs/news-events-human-drugs/fda-announces-new-drug-labeling-information-acetaminophen-during-pregnancy
ACOG statement on acetaminophen use in pregnancy
acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/09/acetaminophen-use-in-pregnancy
Would you like me to also pull the latest appeal status in that multidistrict litigation?
KVUE Just watching Trumps speech now. This stocks in for some pain. Imagine the execs scrambling internally to mount a counter PR campaign against this.KVUE too hot to handle ATM, not sure how much room is left for shorts either as there's no precedent. watchlist for nowtradingview.com/x/MDXN9MYn
KVUE this might be one of the easiest shorts of the year
KVUE this ship is going down as we get closer to that report.
KVUE Where from here?
KVUE I think it is a value company.KVUE Key Factor DetailsCurrent Price $17.95 (as of Sep 5, 2025)
52-Week Range High: ~$25.17 (May 8, 2025) · Low: ~$19.70 (recently reached)
Recent Catalysts Q2 earnings miss, health controversy (Tylenol-autism link), macro pressures
Trading Activity Elevated intraday volume (~58 million shares)
KVUE 4% dividend